Pierre Francotte

Dr. Pierre Francotte


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TDThomas Drapier
Thomas Drapier
PGPierre Geubelle
Pierre Geubelle
CBCharlotte Bouckaert
Charlotte Bouckaert
LNLise Nielsen
Lise Nielsen
SLSaara Kaisa Laulumaa
Saara Kaisa Laulumaa
BPBernard Pirotte
Bernard Pirotte

19 December 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
EGEric Goffin
Eric Goffin
TDThomas Drapier
Thomas Drapier
ALAnja Probst Larsen
Anja Probst Larsen
PGPierre Geubelle
Pierre Geubelle
CPChristopher P. Ptak
Christopher P. Ptak
PFPierre Francotte
Pierre Francotte

1 June 2017 in Molecular Pharmacology
Verified
Journal Article
Open access
PDF file
ALAnja Probst Larsen
Anja Probst Larsen
SFSabine Fièvre
Sabine Fièvre
KFKarla Frydenvang
Karla Frydenvang
PFPierre Francotte
Pierre Francotte
BPBernard Pirotte
Bernard Pirotte
CMChristophe Mulle
Christophe Mulle
Kainate receptors (KARs) consist of a class of ionotropic glutamate receptors, which exert diverse pre- and postsynaptic functions through complex signaling regulating the activity of neural circuits. Whereas numerous small-molecule positive allosteric modulators of the ligand-binding domain of (S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propanoic acid (AMPA) receptors have been reported, no such ligands are available for KARs. In this study, we investigated the ability of three benzothiadiazine-based modulators to potentiate glutamate-evoked currents at recombinantly expressed KARs. 4-cyclopropyl-7-fluoro-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide (BPAM344) potentiated glutamate-evoked currents of GluK2a 21-fold at the highest concentration tested (200 μM), with an EC50 of 79 μM. BPAM344 markedly decreased desensitization kinetics (from 5.5 to 775 ms), whereas it only had a minor effect on deactivation kinetics. 4-cyclopropyl-7-hydroxy-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide (BPAM521) potentiated the recorded peak current amplitude of GluK2a 12-fold at a concentration of 300 μM with an EC50 value of 159 μM, whereas no potentiation of the glutamate-evoked response was observed for 7-chloro-4-(2-fluoroethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide (BPAM121) at the highest concentration of modulator tested (300 μM). BPAM344 (100 μM) also potentiated the peak current amplitude of KAR subunits GluK3a (59-fold), GluK2a (15-fold), GluK1b (5-fold), as well as the AMPA receptor subunit GluA1i (5-fold). X-ray structures of the three modulators in the GluK1 ligand-binding domain were determined, locating two modulator-binding sites at the GluK1 dimer interface. In conclusion, this study may enable the design of new positive allosteric modulators selective for KARs, which will be of great interest for further investigation of the function of KARs in vivo and may prove useful for pharmacologically controlling the activity of neuronal networks.


9 July 2021 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
KEKoffi Sénam Etsè
Koffi Sénam Etsè
JDJerzy Dorosz
Jerzy Dorosz
KCKatrine McLain Christensen
Katrine McLain Christensen
JTJean-Yves Thomas
Jean-Yves Thomas
IPIuliana Botez Pop
Iuliana Botez Pop
PFPierre Francotte
Pierre Francotte

4 November 2018 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
SLSaara Kaisa Laulumaa
Saara Kaisa Laulumaa
KHKathrine Voigt Hansen
Kathrine Voigt Hansen
MMMagdalena Masternak
Magdalena Masternak
TDThomas Drapier
Thomas Drapier
PFPierre Francotte
Pierre Francotte
JKJette Sandholm Kastrup
Jette Sandholm Kastrup